The NADP can support you in finding project partners for projects aimed at the development of new antibiotics and alternative therapies (prevention and care) for human and animal health. You can contact NADP via [email protected] with your questions about matchmaking and opportunities for your own project.
Support researchers and SMEs to bring novel antibiotics and alternatives a step closer to the clinic.
Continuous application - check collection dates
Partnering with AMR Centre (U.K.)
AMR Centre’s accelerates the development of new antimicrobial drugs and diagnostics. As such the AMR Centre works globally with companies and research institutions to support the development of their products from lead optimization through to Phase 2A. The AMR Centre aims to progress circa 5 new projects each year.
Novartis Venture Fund
The Novartis Venture Fund makes equity investments in life science companies focussing on the development of novel therapeutics and platforms. Investments by the Novartis Venture Fund are made as equity participation typically as the lead or co-lead investor in a syndicate with a board seat. The Novartis Venture Fund has a relatively high amount of investments in the domain of infectious diseases.
Strategic actions on product-related implementation research 2019
The purpose of this call for proposals is to support distinct strategic actions to translate medical interventions of proven efficacy (diagnostics, drugs, vaccines, and microbicides) into routine care. Proposals may include testing of delivery methods to increase population coverage, retention in care and adherence to the intervention. We believe that this specific opportunity is a particularly nice fit with the mission from AMR Global.
Pre-applications are expected by 10 October 2019
New drugs and vaccines for priority pathogens in antimicrobial resistance 2019
The purpose of this call for proposals is to provide funding for clinical trials to be conducted in sub-Saharan Africa which aim to develop new or improved medicinal products (drugs and vaccines) or combinations thereof against pathogens from the WHO priority list that also fall within the scope of the EDCTP2 programme, specifically Campylobacter, Salmonella, Streptococcus pneumoniae, and Mycobacterium tuberculosis.
Pre-applications are expected by 7 November 2019
Direct acting small molecules
CARB-X welcomes applications from around the world for funding and support for the early development of antibiotics, diagnostics, vaccines and other products to combat the most serious drug-resistant bacteria. The scope of CARB-X funding is restricted to projects that target drug-resistant bacteria highlighted on the ‘Antibiotic Resistant Threats in the United States’ report published by the Centers for Disease Control and Prevention (CDC) in 2013 or the Priority Bacterial Pathogens list published by the World Health Organization (WHO) in 2017 – with a priority on those pathogens deemed Serious or Urgent on the CDC list or Critical or High on the WHO list.
Pre-applications are expected before 19 November 2019